Ecron receives OrbiMed financing

By Nick Taylor

- Last updated on GMT

Related tags: Contract research organization, Clinical trial

India-based CRO Ecron Acunova will support its geographic expansion and strengthen its service offering after receiving Series B financing from OrbiMed’s Caduceus Asia Mauritius.

The contract research organisation (CRO) has bolstered its presence in several markets in recent months and is looking to build on this with the latest investment. Further financial details of the investment have not been disclosed.

Ecron has built a clinical trial network in India and Central and Eastern Europe and in the second half of this calendar year has made a number of deals to further expand its geographic reach.

Most recently it opened an office in Moscow, Russia to benefit from the “high recruitment rates, low drop-out rates and high quality data​” which can be achieved there, according to Antal Hajos, managing director and CEO of Ecron, Europe.

The establishment of an office in Moscow formalised Ecron’s activities in Russia, where it has operated for several years through collaborations. Over this period the CRO has built relationships with clinical trials sites which should help ease its entry into the market.

Ecron strategic alliances

In the case of Russia Ecron chose to establish its own office but on several other expansions this year it has opted for strategic alliances, such as last month’s deal with Japan-based Tokyo CRO.

This alliance is intended to strengthen Ecron’s offering China, Korea and Japan. D A Prasanna, founder of Ecron, placed particular emphasis on Japan, describing it as a “key market​” with specific requirements for approval of new drug applications (NDA).

These requirements can present challenges to companies seeking to enter the market but by partnering with Tokyo CRO Ecron gains local knowledge. Ecron also partnered with Essential CRO, a trial and recruitment specialist, and Biotrial, a France-based CRO, earlier this year.

OrbiMed believes this offering makes Ecron an attractive investment, with Sunny Sharma, senior managing director of OrbiMed Advisors India, describing the CRO as being “uniquely positioned with talented scientists, excellent network and a broad service portfolio​”.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars